Pacer Advisors’s ALX Oncology ALXO Stock Holding History

Pacer Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,010	Closed	-$74K	–	1412
2021 Q1	$74K	Buy	1,010 +564	+126%	+$44.4K	﹤0.01%	1349
2020 Q4	$38K	Buy	+446	New	+$26.8K	﹤0.01%	1439

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Pacer Advisors's ALXO Position: Q2 2021 in Review

Pacer Advisors sold out of ALX Oncology (ALXO) in Q2 2021, closing a stake of 1,010 shares — an estimated $74K sold.

Pacer Advisors first reported a position in ALXO in Q4 2020 and held it in 2 quarters. The position peaked at $74K in Q1 2021. 104 funds tracked by Wall St. Rank hold ALXO as of Q2 2021.

Pacer Advisors reported no remaining ALX Oncology position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 1,010 ALX Oncology shares in Q2 2021, an estimated $74K.
Pacer Advisors first reported a position in ALX Oncology in Q4 2020 and held it in 2 quarters.
Pacer Advisors's ALX Oncology position peaked at $74K in Q1 2021.
104 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.